歌礼制药-B（股票代码：01672）于2026年6月24日公告，已在香港联交所场内回购普通股20.00万股，约占公司已发行股本的0.0188%。回购价介乎每股9.97港元至10.25港元；此次交易涉资约201.81万港元。
回购完成后，公司已发行股本仍为1,061,370,845股，库存股数维持7,084,210股。从公告可见，此次回购依据2025年5月22日获批的购回授权进行，授权可回购股份总数为96,284,628股，至今累计在包括香港联交所在内的证券交易所回购9,486,000股，占购回授权通过当日已发行股份总数的0.9844%。公司确认已遵守香港联合交易所有限公司证券上市规则以及相关法律规定。本公告由公司秘书钟明辉签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.